Die Unterstützung und Beratung durch Gimv war entscheidend für unsere Bemühungen, bahnbrechende Technologien zu entwickeln, die das Leben von Menschen mit Rückenmarksverletzungen verbessern.
Dave Marver - CEO
ONWARD
ONWARD develops Targeted Epidural Spinal Stimulation (TESS), an implantable neuro stimulator for patients with incomplete spinal cord injury. The company’s device supports motor function recovery for better and faster rehabilitation by stimulating the spinal cord. The company was founded in 2014 as a spin-off of the Center for Neuro-Prosthetics of the renowned École Polytechnique Fédérale de Lausanne (EFPL, Switzerland), where its clinical center is located. Technology development happens in Eindhoven (The Netherlands). ONWARD is led by an experienced management which consists of top level neuroscientists, complemented by entrepreneurs with a track record in developing breakthrough science into products.
This investment will fund the company’s clinical trials up to CE mark (EU) and IDE (US) approval.
Share
2016
50
die Niederlande und die Schweiz
When ambition meets ambition
ONWARD is working with a team of scientists, engineers and physicians, collectively driven to create therapies that change lives. They understand the challenges of those living with spinal cord injury and they do not overpromise.
ONWARD will be there for the highs, lows and everything in between.
Together, we build leading companies
The work of ONWARD builds on more than a decade of basic science and preclinical research conducted at the world's leading neuroscience laboratories. ONWARD's ARC Therapy is designed to deliver targeted, programmed stimulation of the spinal cord to restore movement and other functions in people with spinal cord injury.
We are fortunate to enjoy strong relationships with many of the leading organizations who support research and innovation for individuals and families impacted by paralysis and admire and celebrate the grit, courage and determination shown daily by those we hope to serve.
